Dr. Nitika Taneja and Dr. Ali Akyildiz will receive a Starting Grant from the European Research Council (ERC) this year. The prestigious grant allows young scientists to develop their research projects.
AstraZeneca’s adenovirus-based covid-19 vaccine is associated with a 30 percent increased risk of the rare side effect thrombocytopenia, or too few platelets, compared to Pfizer’s mRNA covid-19 vaccine. This has been confirmed by research coordinated by Erasmus MC’s Department of Medical Informatics, published in The BMJ.
Joining the forces and expertise of clinicians, laboratory specialists and scientists is essential in providing the best care for people with hereditary and familial tumors. Erasmus MC’s ‘Academic Center for Familial and Hereditary tumors’ brings these groups together.
The best way to address risk factors for future pandemics is a One Health approach that balances and optimizes the health of people, animals, and ecosystems. That is the message of the The Independent Task Force on COVID-19 and other Pandemics, which includes Prof Dr Marion Koopmans of the Erasmus MC and Pandemic & Disaster […]
Already 20 years ago, the first study on gene therapy for the bleeding disorder hemophilia B was published. Internist-hematologist Prof Dr Frank Leebeek explains what has happened since then. Is gene therapy the cure for the royal disease?
A commentary in Nature Medicine advocates the proper application of artificial intelligence in healthcare and warns of the dangers of misusing machine learning algorithms.
The omicron BA.1 variant of SARS-CoV-2 is less infectious in the brain and triggers less inflammation in brain cells than the virus variant responsible for the first SARS-CoV-2 wave. This has been shown in research with hamsters and human brain cells by scientists from the Erasmus MC. ‘Good news, but no guarantees for the future.’